戻る Agenda
Session 2, Track B: Why Canada for Conducting Clinical Trials?
Session Chair(s)
Marie-France Goyer, MSc
Director, Clinical Operations
Abcellera, Canada
Rebecca Barnes, MS
Executive Director
Network of Networks (N2), Canada
This interactive, moderated session will highlight the advantages of conducting clinical trials in Canada. It will begin with short talks from several perspectives: a clinical trials infrastructure organization; a Canadian site; a Sponsor; and a CRO. Following these framing talks, attendees will have the opportunity to engage in an interactive discussion with the session moderator and speakers.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize some of the factors that make Canada an appealing and competitive country for clinical trials, from different stakeholder perspectives
- Share perspectives on real and perceived barriers to conducting clinical trials in Canada
- Illustrate some of the unique benefits and truths regarding the conduct of clinical trials in Canada that can be used as a unified message to the global market
Speaker(s)
Highlighting the advantages of conducting clinical trials in Canada
Sonia Brodie, MS
Healthtech Connex, Canada
VP Clinical Research
Perspective from a Research Infrastructure Organization
Susan Marlin, MSc
Clinical Trials Ontario, Canada
President & CEO
Perspective from a Global Sponsor
Tammy Kruger, RN
GlaxoSmithKline (GSK), Canada
National Site Engagement Lead / Clinical Research
Perspective from a Global CRO
Stephane Michel, MSc
IQVIA Canada, Canada
Associate Strategic Site Solutions Director / Patient and Site Centric Solutions
Perspective from a Canadian Site
Michael Barr
Apex Trials, Canada
Director of R&D